
    
      This was a multi-center, uncontrolled, prospective, observational study in participants with
      moderate to severe rheumatic disease (RA, PsA, or AS) who received adalimumab under normal
      clinical practice in accordance with Summary of Product Characteristics (SmPC), with or
      without other anti-rheumatic treatments.
    
  